| 549-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 549-14-4
• 化学式: C8H6MgO4
• 分子量: 190.44
• InChiKey: FAYZSSWSVMJVRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR<br/>[FR] COMPOSÉS DE QUINOLÉINE APPROPRIÉS POUR TRAITER LES AFFECTIONS SENSIBLES À LA MODULATION DES RÉCEPTEURS SÉROTONINERGIQUES 5-HT6
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009019286A1

  公开（公告）日：2009-02-12

  The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.

  本发明涉及公式（I）的新奎诺林化合物及其盐。这些化合物具有有价值的治疗性能，并特别适用于治疗对5-HT6受体调节产生反应的疾病。在公式（I）中，R是公式（R）的基团，其中*表示与喹啉基团的结合位点，A、B、X'、Y、Q、R1、R2、R3、R4、R5、m、n、p、q、Ra、Rb、X和Ar的定义如权利要求书中所述。
• [EN] A METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES<br/>[FR] PROCÉDÉ POUR LA N-DÉMÉTHYLATION DE N-MÉTHYL-HÉTÉROCYCLES
  申请人：UNIV MONASH

  公开号：WO2011032214A1

  公开（公告）日：2011-03-24

  The present invention provides methods of N-demethylating, N-methylated heterocycles and N-methyl, N-oxide heterocycles using a transition metal with an oxidation state of zero, ferrocene or substituted derivatives thereof, or Cr 3+ .N-demethylated heterocycles prepared by the methods of the present invention are also provided.

  本发明提供了使用氧化态为零的过渡金属、二茂铁或其取代衍生物，或Cr 3+ 对N-去甲基化、N-甲基化杂环和N-甲基、N-氧化物杂环的方法。本发明方法制备的N-去甲基化杂环也被提供。
• Phthalazine compounds and therapeutic agents for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US20030105074A1

  公开（公告）日：2003-06-05

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: 1 wherein R 1 and R 2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R 1 is a chlorine atom, R 2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种治疗勃起功能障碍的邻苯二氮杂环化合物，其化学式如下，其药理学上可接受的盐或水合物：1其中，R1和R2相同或不同，表示卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X表示氰基、硝基、卤素原子、可能被取代的羟肟基或可能被取代的杂环基；Y表示杂环基、可能被取代的芳基、可能被取代的炔基、烯基、烷基、可选取代的饱和或不饱和4-至8环胺环，所述的环胺化合物是单环化合物、双环化合物或螺环化合物；l是1到3的整数；但当l为1或2时，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基，Y为取代有羟基的5-或6环胺环时，不在此范围内。
• Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
  申请人：Hall Warren

  公开号：US20050037070A1

  公开（公告）日：2005-02-17

  In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a taste-masking material and one or more antacid are described.

  在本发明的一般方面中，描述了包含质子泵抑制剂微胶囊化的药物配方，该微胶囊化物质增强了药物组合物的货架寿命，同时还包含一种或多种抗酸剂。在本发明的另一一般方面中，描述了包含质子泵抑制剂微胶囊化的药物配方，该微胶囊化物质具有掩味作用，并包含一种或多种抗酸剂。
• Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
  申请人：Hall Warren

  公开号：US20060204585A1

  公开（公告）日：2006-09-14

  In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

  在本发明的一般方面中，描述了含有质子泵抑制剂微囊化或干燥涂层的药物制剂，该涂层增强了药物组成物的货架寿命，并且含有一个或多个抗酸剂。在本发明的另一个一般方面中，描述了含有微囊化或干燥涂层的质子泵抑制剂和一种或多种抗酸剂的药物制剂，该涂层用于掩盖药物的味道。